Literature DB >> 16298154

Recombinant anti-EspA antibodies block Escherichia coli O157:H7-induced attaching and effacing lesions in vitro.

Roberto M La Ragione1, Shila Patel, Ben Maddison, Martin J Woodward, Angus Best, Garry C Whitelam, Kevin C Gough.   

Abstract

Intimin and EspA proteins are virulence factors expressed by attaching and effacing Escherichia coli (AEEC) such as enteropathogenic and enterohaemorrhagic E. coli. The EspA protein makes up a filament structure forming part of the type III secretion system (TTSS) that delivers effector proteins to the host epithelial cell. Bacterial surface displayed intimin interacts with translocated intimin receptor in the host cell membrane leading to intimate attachment of the bacterium and subsequent attaching and effacing lesions. Here, we have assessed the use of recombinant monoclonal antibodies against E. coli O157:H7 EspA and intimin for the disruption of AEEC interaction with the host cell. Anti-gamma intimin antibodies did not reduce either adhesion of E. coli O157:H7 to host cell mono-layers or subsequent host cell actin rearrangement. Anti-EspA antibodies similarly had no effect on bacterial adhesion however they had a marked effect upon E. coli O157:H7-induced host cell actin rearrangement, where both monoclonal and polyclonal antibodies completely blocked cytoskeletal changes within the host cell. Furthermore, these anti-EspA antibodies were shown to reduce actin rearrangement induced by some but not all other AEEC serotypes tested. Both polyclonal and monoclonal antibodies could be used to label E. coli O157 EspA filaments and these immunoreagents did not inhibit the formation of such filaments. This is the first report of monoclonal antibodies to EspA capable of disrupting the TTSS function of E. coli O157:H7.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16298154     DOI: 10.1016/j.micinf.2005.07.009

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  11 in total

1.  Fusion expression and immunogenicity of EHEC EspA-Stx2Al protein: implications for the vaccine development.

Authors:  Yan Cheng; Youjun Feng; Ping Luo; Jiang Gu; Shu Yu; Wei-jun Zhang; Yan-qing Liu; Qing-Xu Wang; Quan-ming Zou; Xu-hu Mao
Journal:  J Microbiol       Date:  2009-09-09       Impact factor: 3.422

2.  Inhibition of Adhesion of Enteropathogenic Escherichia coli to HEp-2 Cells by Binding of a Novel Peptide to EspB Protein.

Authors:  Duoyun Li; Zhong Chen; Hang Cheng; Jin-Xin Zheng; Wei-Guang Pan; Wei-Zhi Yang; Zhi-Jian Yu; Qi-Wen Deng
Journal:  Curr Microbiol       Date:  2016-05-31       Impact factor: 2.188

Review 3.  Type III secretion systems and disease.

Authors:  Bryan Coburn; Inna Sekirov; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

4.  Modified needle-tip PcrV proteins reveal distinct phenotypes relevant to the control of type III secretion and intoxication by Pseudomonas aeruginosa.

Authors:  Hiromi Sato; Meredith L Hunt; Joshua J Weiner; Andrew T Hansen; Dara W Frank
Journal:  PLoS One       Date:  2011-03-29       Impact factor: 3.240

5.  Multi-Functional Characteristics of the Pseudomonas aeruginosa Type III Needle-Tip Protein, PcrV; Comparison to Orthologs in other Gram-negative Bacteria.

Authors:  Hiromi Sato; Dara W Frank
Journal:  Front Microbiol       Date:  2011-07-04       Impact factor: 5.640

6.  In silico analysis of chimeric espA, eae and tir fragments of Escherichia coli O157:H7 for oral immunogenic applications.

Authors:  Jafar Amani; S Latif Mousavi; Sima Rafati; Ali H Salmanian
Journal:  Theor Biol Med Model       Date:  2009-12-08       Impact factor: 2.432

7.  Oral Immunization with Recombinant Lactobacillus acidophilus Expressing espA-Tir-M Confers Protection against Enterohemorrhagic Escherichia coli O157:H7 Challenge in Mice.

Authors:  Ruqin Lin; Yiduo Zhang; Beiguo Long; Yawen Li; Yuhua Wu; Siqin Duan; Bo Zhu; Xianbo Wu; Hongying Fan
Journal:  Front Microbiol       Date:  2017-03-15       Impact factor: 5.640

Review 8.  Antibodies Inhibiting the Type III Secretion System of Gram-Negative Pathogenic Bacteria.

Authors:  Julia A Hotinger; Aaron E May
Journal:  Antibodies (Basel)       Date:  2020-07-27

9.  Antibodies Directed against Shiga-Toxin Producing Escherichia coli Serotype O103 Type III Secreted Proteins Block Adherence of Heterologous STEC Serotypes to HEp-2 Cells.

Authors:  Taseen S Desin; Hugh G Townsend; Andrew A Potter
Journal:  PLoS One       Date:  2015-10-09       Impact factor: 3.240

10.  EspA-Intimin chimeric protein, a candidate vaccine against Escherichia coli O157:H7.

Authors:  Hamid Sedighian Rad; Seyed Latif Mousavi; Iraj Rasooli; Jafar Amani; Moohamad Reza Jalali Nadooshan
Journal:  Iran J Microbiol       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.